Triso
Automatic Anatomic Image Analysis and Evaluation
StartupTriso is a Bet Shemesh-based startup in the Health Tech & Life Sciences sector, established in 2016. Automatic Anatomic Image Analysis and Evaluation. Triso was founded by Michael Lyons and David Abergel. Key investors include Undisclosed Investor(s). The company has 11-50 employees. Core technologies: Simulation & Imaging.
The company follows a B2B business model. Product stage: Alpha. The company holds 1 patent.
- StageSeed
- ProductAlpha
- ModelB2B
- Employees11-50
- HQBet Shemesh
- DistrictJerusalem District
- Last RoundUndisclosed
- Undisclosed Investor(s)
Michael LyonsCo-founder & CEO
David AbergelCo-founder & CTO
What does Triso do?
Triso is developing a platform for the automatic analysis and evaluation of anatomic images. The platform has a wide range of functionalities and can service a variety of medical disciplines. Its software is capable of accurately determining and precisely defining the boundaries of anatomic features from ultrasounds, CTs, and X-rays. Triso's patented imaging platform is developed in two modalities. The LV-Tricardio is a fully automated echocardiogram imaging platform, and the TriAngeo platform automatically traces the network arteries across an angiogram image, providing data on the entire arterial network.
Who founded Triso?
Triso was founded in 2016 by Michael Lyons (Co-founder & CEO), David Abergel (Co-founder & CTO).
What sector is Triso in?
Triso operates in Health Tech & Life Sciences, Digital Healthcare, Digital Medical Diagnostics, with core technologies in Simulation & Imaging. Target customers: Healthcare & Life Sciences, Healthcare, Providers.
Where is Triso located?
Triso is based in Bet Shemesh, Israel, Jerusalem District.